ASCO 2018 | CAR T-cells in myeloma: are they as promising as we think?

Faith Davies

With the impressive results from initial trials using CAR T-cells, excitement surrounding this modality as a curative therapy was high. However, as explained here by Faith Davies MD, MRCP, MRCPath, FRCPath, from UAMS Myeloma Institute, Little Rock, AR, CAR T-cells are still far from a curative therapy for multiple myeloma. Dr Davies highlights the additional work required if these impressive response rates are to be maintained, with a number of important questions remaining. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Share this video